类风湿关节炎(RA)是一种以侵蚀性关节炎症为主要临床表现的自身免疫性疾病,可发生于任何年龄【1-2】。目前,RA的发病机制尚不明确,其基本病理表现为关节内滑膜炎症、血管翳形成等,随着病程进展会逐渐出现关节软骨和骨破坏,最终导致关节畸形和功能丧失【3-4】。RA的危害不仅局限在骨关节方面,它还可能并发肺部疾病、心血管疾病、恶性肿瘤及抑郁症等疾病,严重危害患者的身体健康。 流行病学调查显示,RA的全球发病率0.5%~1%【1】,中国大陆地区发病率为0.42%,总患病人群约500万,男女患病比率约为1∶4【5】。我国RA患者在病程1~5年、5~10 年、10~15 年及≥15 年的致残率分别18.6%、43.5%、48.1%、61.3%,病程越长,患者残疾以及功能受限的发生率越高【5】。 因此,尽早采取科学 、规范的治疗方案对提高患者生活质量、社会活动参与度,减轻社会和家庭经济负担至关重要。 根据患者疾病的不同阶段采取不同的治疗方案是最基本、也是最重要的治疗原则之一。在临床上,RA的治疗方法有很多,但是各个疾病阶段该采取哪种治疗,一直困扰着医务人员和RA患者。 类风湿关节炎病程分期 不同分期治疗方案的选择 早期治疗方法 中期治疗方法 晚期治疗方法 总结与补充 参考文献: [1] Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis[J]. Lancet,2016, 388 (10055):2023-2038.DOI:10.1016/S0140-6736(16)30173-8. [2] McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis[J]. Lancet, 2017, 389(10086):2328-2337. DOI: 10.1016/S01406736(17)31472-1. [3] Mcinnes IB, Schett G. The pathogenesis of rheumatoid arthritis[J]. N Engl J Med, 2011, 365(23):2205-2219. DOI: 10.1056/NEJMra1004965. [4] Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis[J]. Lancet, 2017, 389(10086):2338-2348.DOI: 10.1016/S0140-6736(17)31491-5. [5] 中华医学会风湿病学分会.2018中国类风湿关节炎诊疗指南[J]. 中华内科杂志,2018,4(54):242-251. [6] 周兰,沈晓凡.类风湿性关节炎临床分期辩证论治初探【J】.蚌埠医学院学报,1992,17(1):62-63. [7]Riemsma RP, Kirwan JR, Taal E, et al. Patient education for adults with rheumatoid arthritis[J]. Cochrane Database Syst Rev,2003, (2):CD003688. DOI: 10.1002/14651858.CD003688. [8] 张颖, 梁东风, 黄烽. 重视风湿病患者的心身医学研究[J]. 中华内科杂志, 2017, 56(3):163-166. DOI: 10.3760/cma.j.issn.0578-1426.2017.03.002. [9] Proudman SM, James MJ, Spargo LD, et al. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use[J]. Ann Rheum Dis, 2015, 74(1):89-95. DOI: 10.1136/annrheumdis-2013-204145. [10] He J, Wang Y, Feng M, et al. Dietary intake and risk of rheumatoid arthritis-a cross section multicenter study[J].Clin Rheumatol,2016,35(12):2901-2908.DOI:10.1007/s10067-016-3383-x. [11]Xu B, Lin J. Characteristics and risk factors of rheumatoid arthritis in the United States: an NHANES analysis[J]. PeerJ,2017, 5:e4035. DOI:10.7717/peerj.4035. [12] Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies[J]. Ann Rheum Dis,2010, 69(1):70-81. DOI: 10.1136/ard.2008.096487. [13] do Carmo CM, Almeida da Rocha B, Tanaka C. Effects of individual and group exercise programs on pain, balance,mobilityand perceived benefits in rheumatoid arthritis withpain and footdeformities[J]. J Phys Ther Sci, 2017, 29(11):1893-1898. DOI: 10.1589/jpts.29.1893. [14] Hurkmans E, Van der Giesen FJ, Vliet Vlieland TP, et al.Dynamic exercise programs (aerobic capacity and/or musclestrength training) in patients with rheumatoid arthritis[J].Cochrane Database Syst Rev, 2009, 7(4):CD006853. DOI: 10.1002/14651858.CD006853.pub2. [15] Han A, Robinson V, Judd M, et al. Tai chi for treating rheumatoid arthritis[J]. Cochrane Database Syst Rev, 2004, (3):CD004849. DOI: 10.1002/14651858.CD004849. [16] Cramp F, Hewlett S, Almeida C, et al. Non-pharmacological interventions for fatigue in rheumatoid arthritis[J]. Cochrane Database Syst Rev, 2013, 23(8):997-1005. DOI: 10.1002/14651858.CD008322.pub2. [17] Saudan M, Saudan P, Perneger T, et al. Celecoxib versusibuprofen in the prevention of heterotopic ossification followingtotal hip replacement: a prospective randomised trial[J]. J BoneJoint Surg Br, 2007, 89(2):155-159. [18]苏哲,张宁.托珠单抗治疗中重度类风湿关节炎的临床研究[J]. 实用药物与临床,2019,22(5):526-529. [19] 田新平, 曾小峰. 共刺激分子CTLA4的研究进展及在风湿病治疗中的应用[J]. 基础医学与临床,2006,26(9):942-946. [20] van der Heijde D, Klareskog L, RodriguezValverde V, etal. Comparison of etanercept and methotrexate, alone andcombined, in the treatment of rheumatoid arthritis: two-yearclinical and radiograhpic results from the TEMPO study, adouble-blind, randomized trial[J]. Arthritis Rheum, 2006,54(4):1063-1074. [21] van der Heijde D, Klareskog L, LandewP R, et al. Diseaseremission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis[J]. Arthritis Rheum, 2007, 56(12):3928-3939. [22]张溢凡.JAK抑制剂在类风湿性关节炎治疗中的研究进展[J].精细化工中间体,2018,48(3):10-14. [23] Li J, Mao H, Liang Y, et al. Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis[J]. Clin Dev Immunol,2013, 2013(7):310628. DOI: 10.1155/2013/310628. [24] Hara M, Ishiguro N, Katayama K, et al. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial[J]. Mod Rheumatol, 2014, 24(3):410-418. DOI: 10.3109/14397595.2013.843756. [25]张家永 郭进 沈洁等. MTX联合艾拉莫德治疗难治性类风湿关节炎的临床观察【J】. Guide of China Medicine,2014,1(12):98-99. [26] Lau CS, Chia F, Harrison A, et al. APLAR rheumatoid arthritis treatment recommendations[J]. Int J Rheum Dis,2015, 18(7):685-713. DOI: 10.1111/1756-185X.12754. [27] Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update[J]. Ann Rheum Dis, 2017, 76(6):960-977.DOI: 10.1136/annrheumdis-2016-210715. [28] Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial[J]. Lancet, 2017,390(10093):457-468. DOI:10.1016/S0140-6736(17)31618-5. [29] Bergrath E, Gerber RA, Gruben D, et al. Tofacitinib versus Biologic Treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: systematic literature review and network meta-analysis[J]. Int J Rheumatol, 2017, 2017:8417249. DOI:10.1155/2017/8417249. [30]Vieira MC, Zwillich SH, Jansen JP, et al. Tofacitinib versus biologic treatments in patients with active rheumatoid arthritis who have had an inadequate response to tumor necrosis factor inhibitors: results from a network meta-analysis[J]. Clin Ther,2016, 38(12):2628-2641. DOI: 10.1016/j.clinthera.2016.11.004. [31] Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis[J]. N Engl J Med,2012, 367(6):495-507. DOI: 10.1056/NEJMoa1109071. [32]Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis[J]. Cochrane Database Syst Rev, 2007, 1(1): CD006356. DOI: 10.1002/14651858.CD006356. [33] Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis[J]. Ann Rheum Dis, 2010, 69(6):1010-1014. DOI: 10.1136/ ard.2009.127332. [34] 刘升云, 杨璐, 张磊, 等. 甲氨蝶呤联合小剂量泼尼松治疗类风湿关节炎的短期疗效与安全性[J]. 中华内科杂志,2013, 52(12):1018-1022. DOI: 10.3760/cma.j.issn.0578-1426.2013.12.006. |
|